An accessible digital single-molecule sensing platform for plasma P-tau217 quantification in Alzheimer's disease screening.
The DiSMS platform enables accurate, cost-accessible plasma P-tau217 quantification for AD screening, meeting consensus guidelines (≥90%), and the limited P-tau217 performance for differentiating AD from FTD highlights the need for integration with complementary biomarkers or clinical assessments.